Terbutaline


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult: PO Acute bronchospasm Initial: 2.5 mg or 3 mg tid, up to 5 mg tid as necessary. As modified-release tab: 5 mg or 7.5 mg bid. Inhalation Acute bronchospasm As metered-dose powd inhaler: 250-500 mcg as required. Max: 2,000 mcg/day. Severe bronchospasm As 1% nebuliser soln: 2.5-10 mg 2-4 times/day. IM/IV/SC Severe bronchospasm 250-500 mcg up to 4 times/day by SC, IM or IV inj, or by IV infusion as a soln containing 3-5 mcg/mL at a rate of 0.5-1 mL/min. IV Uncomplicated premature labour 22-37 wk of gestation: Initial: 5 mcg/min, w/ increments of 2.5 mcg/min at 20 min intervals until contractions stop. Max: 20 mcg/min. Continue for 1 hr after contractions have ceased, then decrease by 2.5 mcg/min every 20 min to lowest dose that maintains suppression. Max duration: 48 hr.
Administration
May be taken with or without food.
Contraindications
Parenteral: Prolonged (beyond 48-72 hr) or maintenance tocolysis, particularly in outpatient or home setting. PO: Acute or maintenance tocolysis.
Special Precautions
Patient w/ thyrotoxicosis, HTN, DM, ketoacidosis, CV disorders (e.g. ischaemic heart disease), convulsive disorders, coronary insufficiency or associated arrhythmias. Childn. Pregnancy and lactation. Monitoring Parameters Monitor cardiorespiratory function, serum K and glucose levels; signs/symptoms of pulmonary oedema (when used in premature labour).
Adverse Reactions
Tachycardia, nervousness, tremor, palpitations, dizziness, headache, nausea, vomiting, anxiety, restlessness, lethargy, drowsiness, weakness, flushes, sweating, chest discomfort, muscle cramps, tinnitus. Rarely, seizures, hypersensitivity vasculitis, elevated liver enzymes.
Potentially Fatal: Increased heart rate, transient hyperglycaemia, hypokalaemia, cardiac arrhythmias, pulmonary oedema, myocardial ischaemia.
Drug Interactions
Increased risk of haemorrhage and serious ventricular rhythm disorder w/ halogenated anaesth. May reduce the effect of anti-diabetic drugs. Increased risk of hypokalaemia w/ K-depleting agents (e.g. diuretics). Concomitant β-agonist and corticosteroid may result to pulmonary oedema. May partially or totally inhibit the effect of non-selective β-blockers.
ATC Classification
R03AC03 - terbutaline ; Belongs to the class of adrenergic inhalants, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
R03CC03 - terbutaline ; Belongs to the class of adrenergics for systemic use, selective beta-2-adrenoreceptor agonists. Used in the treatment of obstructive airway diseases.
Disclaimer: This information is independently developed by CIMS based on terbutaline from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 CIMS. All rights reserved. Powered by CIMSAsia.com
MORE
LESS
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in